An important objective of the POl application is to define the contribution of altered sphingolipid metabolism in Acute Myeloid Leukemia (AML). Through the multiple Projects, the roles of specific sphingolipids and sphingolipid enzymes in AML and the efficacy of therapeutically targeting sphingolipid metabolism for AML will be defined. In order to achieve these objectives the Targeted Sphing
Acute Myeloid Leukemia (AML) is the most common acute leukemia affecting adults. The complexity of AML is attributed to multiple subtypes based on cyto- and molecular-genetics. This Core serves a role in hypothesis generation for the Projects by seeking to understand alterations in sphingoiipid and glycosphingolipid metabolism within different subsets of patients with AML and hypothesis testing by providing standardized measurements of the sphingoiipid pathways. The outcome of tfiese studies will help validate and define new sphingolipid-based therapeuWc targets for AML.